Business Wire Health News

PREIT Announces New Healthcare Center at Plymouth Meeting Mall

Thu, 9 Feb 2012 21:30:00 UT

PHILADELPHIA--(BUSINESS WIRE)--Pennsylvania Real Estate Investment Trust (PREIT/NYSE: PEI) today announced an agreement to introduce a Mercy Health System consumer health and wellness satellite aligned with Mercy Suburban Hospital. The 23,500 square foot two-level outpatient ambulatory healthcare facility is scheduled to open at Plymouth Meeting Mall in suburban Philadelphia in September 2012. The facility will include primary care physician and specialist offices, physical therapy and non-invas

Gilead Sciences to Present at Two Upcoming Investor Conferences

Thu, 9 Feb 2012 21:30:00 UT

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gilead’s President and Chief Operating Officer, will be participating in “fireside chat” forums at two upcoming investor conferences taking place in New York. The first will take place at the BIO CEO & Investor Conference, available via a replay on Gilead’s website after 4:00 p.m. Eastern Time (ET), on Tuesday, February 14. The second will occur at the Leerink Swan Global He

Zalicus and Hydra Collaborate to Advance Novel Ion Channel Product Candidates for the Treatment of Pain

Thu, 9 Feb 2012 21:30:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus and Hydra Biosciences collaborate to advance development of Zalicus’ preclinical ion channel modulator product candidates for the treatment of pain.

Health Management Associates, Inc. to Present at the Leerink Swan 2012 Global Healthcare Conference

Thu, 9 Feb 2012 21:18:00 UT

NAPLES, Fla.--(BUSINESS WIRE)--Health Management Associates, Inc. (NYSE: HMA) announced today that its management will present at the Leerink Swan 2012 Global Healthcare Conference to be held February 15-16, 2012 at The Waldorf=Astoria in New York City. Health Management’s senior leaders will present on Thursday, February 16, 2012 at 1:30 PM ET. The presentation will be webcast live over the Internet via Health Management's website (http://www.hma.com). Listeners are encouraged to go to the Inve

CEL-SCI Corporation Reports First Quarter 2012 Financial Results

Thu, 9 Feb 2012 21:15:00 UT

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) reports financial results for the fiscal quarter ended December 31, 2011. CEL-SCI reported that net loss available to shareholders for the quarter ended December 31, 2011 was ($4,156,833) versus ($6,250,952) during the same quarter ended December 31, 2010. Net loss per common share, (basic) was ($0.02) for the quarter ended December 31, 2011 versus ($0.03) during the same quarter ended December 31, 2010. The operating loss for th

Synageva BioPharma Announces Interim Data at 8th Annual Lysosomal Disease Network (LDN) World Symposium

Thu, 9 Feb 2012 21:10:00 UT

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced encouraging safety and tolerability data as well as effects consistent with preclinical findings and known mechanism of action. Patients from this 4-week Phase I/II trial of SBC-102 in adults with late onset LAL Deficiency continue to transition into an open-label extension study. “Patients with LAL

Exelixis Announces Proposed Public Offering of Common Stock

Thu, 9 Feb 2012 21:09:00 UT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock in connection with the offering. All of the shares in the offering will be sold by Exelixis. The shares will be issued pursuant to a prospectus

PharMerica Reports Strong Results for the Fourth Quarter of 2011 and Year Ended December 31, 2011

Thu, 9 Feb 2012 21:05:00 UT

LOUISVILLE, Ky.--(BUSINESS WIRE)--PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today reported its financial results for the fourth quarter of 2011 and year ended December 31, 2011. Commenting on the Company’s results for the fourth quarter, Gregory S. Weishar, PharMerica Corporation’s Chief Executive Officer, said, “Fourth quarter’s strong results clearly demonstrate PharMerica’s potential as we continue to benefit f

Five Star Quality Care, Inc. Fourth Quarter Conference Call Scheduled for Thursday, February 16th

Thu, 9 Feb 2012 21:01:00 UT

NEWTON, Mass.--(BUSINESS WIRE)--Five Star Quality Care, Inc. (NYSE: FVE) today announced that it will host a conference call in conjunction with the announcement of its fourth quarter 2011 financial results. Five Star plans to issue a press release containing its fourth quarter 2011 financial results before the NYSE opens on Thursday, February 16, 2012. Later that morning, at 10:00 a.m. Eastern Time, Bruce Mackey, President and Chief Executive Officer, and Paul Hoagland, Chief Financial Officer,

Senior Housing Properties Trust Fourth Quarter Conference Call Scheduled for Thursday, February 16th

Thu, 9 Feb 2012 21:01:00 UT

NEWTON, Mass.--(BUSINESS WIRE)--Senior Housing Properties Trust (NYSE: SNH) today announced that it will host a conference call in conjunction with the announcement of its fourth quarter 2011 financial results. SNH plans to issue a press release containing its fourth quarter 2011 financial results before the NYSE opens on Thursday, February 16, 2012. Later that afternoon, at 1:00 p.m. Eastern Time, David Hegarty, President and Chief Operating Officer, and Richard Doyle, Chief Financial Officer,

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

Thu, 9 Feb 2012 21:01:00 UT

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December 31, 2011. “The first quarter of fiscal 2012 saw transformational change for Arrowhead,” said Dr. Christopher Anzalone, President and Chief Executive Officer. “With the acquisition of the Roche’s RNAi assets and facility, we now have a more complete set of capab

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results

Thu, 9 Feb 2012 21:00:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2011, and company highlights. “2011 was a year of remarkable clinical achievement for Alnylam and for RNAi therapeutics. Notably, we reported on positive clinical data in three distinct programs over the past 12 months, including human proof of RNAi mechanism in our ALN-VSP liver cancer program

Alkermes’ Corporate Presentation to be Webcast at the Leerink Swann 2012 Global Healthcare Conference

Thu, 9 Feb 2012 21:00:00 UT

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Leerink Swann 2012 Global Healthcare Conference on Thursday, Feb. 16, 2012, at 3:00 p.m. EST (8:00 p.m. GMT) from the Waldorf=Astoria Hotel in New York City. The presentation may be accessed under the Investor tab on www.alkermes.com and will be archived for 14 days. Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expert

The Camden Riversharks and AmeriHealth New Jersey Team Up to Promote Health and Wellness to Kids

Thu, 9 Feb 2012 20:56:00 UT

CRANBURY, N.J.--(BUSINESS WIRE)--Forget the peanuts and Cracker Jacks, it’s time for the kiddies to consider some healthier snacks. For the second year, the Camden Riversharks and AmeriHealth New Jersey have partnered to help promote healthy and active lifestyles to the children of Southern New Jersey and Philadelphia. The “Line Drives for Healthy Lives” school assembly program was designed for area elementary schools, to promote and educate children on the importance of eating healthy and stayi

New Precision Engineered Products (PEP) Branding Reflects Stronger, More Unified Company

Thu, 9 Feb 2012 20:51:00 UT

ATTLEBORO, Mass.--(BUSINESS WIRE)--Precision Engineered Products is implementing a new visual identity across its brand family, reflecting a new era for the company, which serves the medical, energy, and transportation industries.

Medical Components, Inc. Awarded Agreement for Three Venous Access Catheter Categories with Novation LLC

Thu, 9 Feb 2012 20:44:00 UT

HARLEYSVILLE, Pa.--(BUSINESS WIRE)--Medcomp has been awarded a 36-month agreement with Novation to be a valued supplier of Hemodialysis, Peritoneal Dialysis and Apheresis Catheters, PICCs, and Implantable Infusion Ports.

Will California Finally Legalize Marijuana? Study Shows 62% of California Voters Polled Favor Legalization

Thu, 9 Feb 2012 20:35:00 UT

LOS ANGELES--(BUSINESS WIRE)--A Full Study Released Shows 62% of California Voters Polled Favor Legalization.

Getting Serious About Psoriasis

Thu, 9 Feb 2012 19:58:00 UT

--(BUSINESS WIRE)--Psoriasis affects as many as 7.5 million Americans--but they can get help to manage it once they take the first step.

Branham Law Group Investigates Pfizer for Qualitest Packaging Error Recall

Thu, 9 Feb 2012 19:19:00 UT

DALLAS--(BUSINESS WIRE)--Branham Law Group, LLP investigates recall of Ethinyl Estradiol, Norgestrel packaging errors.

IDS to Debut Latest Mobile Apps at HIMSS 2012

Thu, 9 Feb 2012 19:15:00 UT

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--IDS mobile apps unify worklists and improve accessibility. Providers can wirelessly authenticate verbal orders, dictate patient encounters, remotely sign reports, and document billing levels.

Extend Health Survey: As Debate Continues over the Future of Medicare, Survey Reveals Seniors’ Q42011 Confidence in Medicare Declined to 62% from Previous Quarter High of 73%

Thu, 9 Feb 2012 19:12:00 UT

SAN MATEO, Calif--(BUSINESS WIRE)--Medicare confidence among seniors declines in Q4 2011

Carter Validus Mission Critical REIT Acquires $8,470,000 Ambulatory Surgical Center

Thu, 9 Feb 2012 19:10:00 UT

TAMPA, Fla.--(BUSINESS WIRE)--Carter Validus Mission Critical REIT Acquires $8,470,000 Ambulatory Surgical Center

FDA’s Oncologic Drugs Advisory Committee (ODAC) Votes to not Support Benefit/Risk Profile of DACOGEN® (decitabine) in Acute Myeloid Leukemia

Thu, 9 Feb 2012 18:46:00 UT

DUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) today announced that the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one person abstaining that data in our partner Eisai’s supplemental new Drug Application (sNDA) for DACOGEN® (decitabine) for Injection did not support a favorable benefit-risk profile for the treatment of acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered ca

Health SolutionsPlus Named Winner in Sixth Annual Paybefore Awards

Thu, 9 Feb 2012 18:19:00 UT

MINNEAPOLIS--(BUSINESS WIRE)--Evolution1™ announced today that Paybefore has chosen Health SolutionsPlus as a 2012 Paybefore Awards winner in the Best Health Care/Health Benefits Prepaid Program category.

Research and Markets: Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others - Read More Inside this 2012 Report

Thu, 9 Feb 2012 18:09:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5de435/commercializing_an) has announced the addition of the "Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others" report to their offering. This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The repo

陶氏益农与保诺就作物保护发现研究展开合作

Thu, 9 Feb 2012 18:02:00 UT

印第安纳波利斯和北卡罗来纳州威尔明顿--(BUSINESS WIRE)--Dow AgroSciences and BioDuro announced a three-year, multi-program discovery research agreement to generate novel molecules for synthesizing and testing fungicides, insecticides, and herbicides.

Ron Paul Issues Statement on Obama Contraception Decision

Thu, 9 Feb 2012 17:57:00 UT

LAKE JACKSON, Texas--(BUSINESS WIRE)--Congressman and 2012 Republican Presidential candidate Ron Paul issued the following statement regarding the Obama Administration's announcement that religious organizations must pay for contraception and sterilization under the national health care law: “Forcing private religious institutions to pay for contraception and sterilization as part of their health care plans is a direct assault on the First Amendment's guarantee of religious liberty. On my first

Ligand to Present at the BIO CEO and Investor Conference on February 13

Thu, 9 Feb 2012 17:45:00 UT

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand will present at the BIO CEO and Investor Conference on Monday, February 13, 2012 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time). The conference takes place at Waldorf-Astoria in New York. A live webcast of the presentation will be available on the Company’s website www.ligand.com. A replay of the presentation will be archived on the

Alejandro Villageliu Joins Heartbeat Ideas as Group Account Director

Thu, 9 Feb 2012 17:19:00 UT

NEW YORK--(BUSINESS WIRE)--Top pharmaceutical marketing executive, Alejandro Villageliu, has joined Heartbeat Ideas' Client Services team as Group Account Director.

2011 Health Spending Growth Remains Near Historic Lows

Thu, 9 Feb 2012 17:15:00 UT

ANN ARBOR, Mich.--(BUSINESS WIRE)--2011 HEALTH SPENDING GROWTH REMAINS NEAR HISTORIC LOWS

SmartBrief Partners with School Nutrition Association to Deliver Vital News to School Nutrition Professionals

Thu, 9 Feb 2012 17:07:00 UT

WASHINGTON--(BUSINESS WIRE)--SmartBrief Inc. and the School Nutrition Association have partnered to produce SNA SmartBrief, a digital media news service containing the latest news and trends for the school nutrition industry.

Health Economics and Outcomes Research Capability Critical for New Product Success

Thu, 9 Feb 2012 17:05:00 UT

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pharmaceutical and biotechnology companies are adapting to a more complex healthcare landscape by better demonstrating the value of their products to private payers, government payers and others.

AtriCure Announces February Investor Conference Schedule

Thu, 9 Feb 2012 17:00:00 UT

WEST CHESTER, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced that it will participate in the following upcoming investor conferences: The Leerink Swann 2012 Global Healthcare Conference at the Waldorf Astoria hotel in New York. Management is scheduled to present on Thursday, February 16, 2012 at 11:30 a.m. Eastern Time. The 2012 RBC Capital

Simmons Law Firm Donates $100,000 to Raise Awareness About Dangers of Asbestos and Mesothelioma

Thu, 9 Feb 2012 16:44:00 UT

ALTON, Ill.--(BUSINESS WIRE)--The Simmons Firm, a leading asbestos and mesothelioma law firm, will be a platinum sponsor of the 8th Annual International Asbestos Awareness Conference. The conference, organized by the Asbestos Disease Awareness Organization (ADAO), will be held March 30-April 1, 2012, at the Manhattan Beach Marriott in Manhattan Beach, Calif., to bring leading international experts together to discuss asbestos as a global public health crisis. “The Asbestos Disease Awareness Orga

Health Reform to Require Insurers to Use Plain Language in Describing Health Plan Benefits, Coverage

Thu, 9 Feb 2012 16:41:00 UT

WASHINGTON--(BUSINESS WIRE)--People in the market for health insurance will soon have clear, understandable and straightforward information on what health plans will cover, what limitations or conditions will apply, and what they will pay for services thanks to the Affordable Care Act – the health reform law – according to final regulations published today. The marketing materials that insurers use can sometimes make it difficult for consumers to understand exactly what they are buying. The new

Arizona Pediatric Cardiology Consultants Receives Pediatric Transthoracic and Fetal Echocardiography Accreditation

Thu, 9 Feb 2012 16:00:00 UT

PHOENIX--(BUSINESS WIRE)--Arizona Pediatric Cardiology Consultants has been granted a three-year term of accreditation by ICAEL.

AirStrip Technologies Announces Investment from Qualcomm

Thu, 9 Feb 2012 15:58:00 UT

SAN ANTONIO--(BUSINESS WIRE)--AirStrip Technologies, Inc. announced that it has received a strategic investment from Qualcomm Incorporated, acting through its Qualcomm Life Fund.

Repligen Announces Conference Call of Preliminary Third Quarter Fiscal Year 2012 Results

Thu, 9 Feb 2012 15:58:00 UT

WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ:RGEN) announced today that it will disclose preliminary financial results for the third quarter of fiscal year 2012 on Tuesday, February 21, 2012, before the market opens. The Company will host a conference call and webcast on the same day at 10 a.m. EST, to discuss the financial results and provide a quarterly corporate update. This call is being webcast by Thomson/CCBN and can be accessed via Repligen’s website at www.repligen.com.

ML Strategies Adds to Growing Health Care Practice

Thu, 9 Feb 2012 15:55:00 UT

WASHINGTON--(BUSINESS WIRE)--ML Strategies is continuing the expansion of its health care practice with the addition of Robert (Bob) Skinner to the firm’s Washington, DC office. ML Strategies is the government affairs and communications affiliate of the law firm Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Mr. Skinner is joining ML Strategies as a Manager of Government Relations and will focus on health care clients. Mr. Skinner worked for Senator Christopher S. (Kit) Bond (R-MO) for thr

SmartCare Urgent Care Welcomes Dr. Zobair Nagamia as Chief Operating Officer

Thu, 9 Feb 2012 15:51:00 UT

ATLANTA--(BUSINESS WIRE)--Dr. Zobair Nagamia has been named Chief Operating Officer of SmartCare Urgent Care located at 4400 Peachtree Road, NE, according to Samir Bhatia, CEO of SmartCare. Located next to Oglethorpe...

Scottish Government and PPD Announce Strategic Alliance to Advance Clinical Research in Scotland

Thu, 9 Feb 2012 15:38:00 UT

EDINBURGH, SCOTLAND & WILMINGTON, N.C.--(BUSINESS WIRE)--The Scottish government and Pharmaceutical Product Development, LLC (PPD) announced a unique alliance designed to increase the amount of clinical research conducted in Scotland.

Colloquium Accredits IU Health as First Heart Failure System in US

Thu, 9 Feb 2012 15:35:00 UT

COLUMBUS, Ohio--(BUSINESS WIRE)--The Healthcare Accreditation Colloquium accredits Indiana University Health as first Colloquium Accredited Heart Failure System in the US. Colloquium focus is ‘relationship-based care.'

Greatbatch, Inc. to Host Fourth Quarter 2011 Earnings Conference Call on February 23, 2012

Thu, 9 Feb 2012 15:24:00 UT

CLARENCE, N.Y.--(BUSINESS WIRE)--Greatbatch, Inc. (NYSE: GB) announced today that it will host a conference call on Thursday, February 23, 2012 at 4:30 p.m. E. T. to discuss its financial results for the fourth quarter and full-year ended December 30, 2011. The earnings conference call can be accessed from the Greatbatch Web site at www.greatbatch.com. A press release detailing the financial results will be issued after the market closes on February 23, 2012. About Greatbatch, Inc. Greatbatch, I

Rite Aid Awarded American Pharmacists Association's Award for 2011-12 Immunization Program

Thu, 9 Feb 2012 15:01:00 UT

CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid (NYSE: RAD) has been honored with the American Pharmacists Association's Immunization Champion Award for its emphasis on vaccinating against flu, shingles, whooping cough and other diseases.

Texas Hospital Association Endorses Care Logistics

Thu, 9 Feb 2012 15:00:00 UT

ATLANTA--(BUSINESS WIRE)--Care Logistics will be working with the Texas Hospital Association (THA) and its marketing subsidiary, HealthSHARE, as part of the five year agreement recently announced with Jackson Healthcare, Care Logistics’ parent company, to identify the first Texas hospitals who will benefit from Care Logistics Hospital Operating SystemTM Solution. THA and HealthSHARE’s endorsement of Care Logistics is an acknowledgment of its industry leadership in achieving total hospital effici

Research and Markets: Generic Pharmaceuticals Market - A Global Analysis

Thu, 9 Feb 2012 14:59:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/1db18a/generic_pharmaceut) has announced the addition of Frost & Sullivan's new report "Generic Pharmaceuticals Market - A Global Analysis" to their offering. Time is Ripe for Generics Manufacturers as Key Blockbuster Drugs Set to go Off-patent The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and th

ForeverGreen’s CEO Eyes Japan for International Growth

Thu, 9 Feb 2012 14:45:00 UT

OREM, Utah--(BUSINESS WIRE)--ForeverGreen Worldwide Corporation (OTCBB: FVRG.OB), a leading provider of nutritional foods and other healthy products, today announced that company CEO Ron Williams traveled to Japan last week to launch new growth initiatives. ForeverGreen views the Asian country as a hot spot for the company’s international growth and for good reason. Japan ranks as No. 2 in the direct sales revenues behind only the U.S., according to the World Foundation for Direct Sales Associat

In 2020, Regeneron/Bayer Healthcare’s Eylea Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Diabetic Macular Edema

Thu, 9 Feb 2012 14:39:00 UT

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, Regeneron/Bayer HealthCare’s Eylea will earn Decision Resources’ proprietary clinical gold standard status for the treatment of diabetic macular edema in 2020. Owing to its competitive advantages in delivery, Eylea (which will launch for the indication in 2016) w

Synergy Pharmaceuticals participará en el XIV Congreso Anual BIO CEO & Investor

Thu, 9 Feb 2012 14:30:00 UT

NUEVA YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP), desarrollador de nuevos fármacos para el tratamiento de enfermedades gastrointestinales, ha anunciado que su Presidente y CEO, Gary S. Jacob, Ph.D, participará en el XIV Congreso Anual BIO CEO & Investor. La presentación de Jacob tendrá lugar el lunes, 13 de febrero, 2012 a las 21:30 (hora peninsular española) en el vestíbulo este del Waldorf Astoria en Nueva York. Acerca de Synergy Pharmaceuticals, Inc. Synergy Pharm

Research and Markets: Thought Leader Insight & Analysis Report Anticoagulants Q3 2011

Thu, 9 Feb 2012 14:30:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/4860ae/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report Anticoagulants Q3 2011" report to their offering. This report reviews the key competitive dynamics taking place in the antiplatelets and antithrombotics (anticoagulants) categories. Medpredict interviewed six internationally recognized experts for this panel and bring together their perspectives, opinio

Research and Markets: Thought Leader Insight & Analysis Report - Cardiovascular Q4 2011

Thu, 9 Feb 2012 14:30:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/5eb1d8/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Cardiovascular Q4 2011" report to their offering. Cardiovascular Thought Leader Panel tackles the complex question of combined use of antithrombotics and antiplatelets in the chronic management of acute coronary syndrome. There have been a number of negative trials of late, most recently the Ph-II RED

Patterson Companies 3rd Quarter Fiscal 2012 Conference Call Scheduled for Thursday, February 23

Thu, 9 Feb 2012 14:30:00 UT

ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies (Nasdaq: PDCO) today announced that it will hold its conference call to review operating results for the third quarter of fiscal 2012 on Thursday, February 23 at 10:00 AM Eastern. The Patterson earnings release will be issued before the market opens that day. Investors can access a live webcast of the conference call by visiting the investor relations section of the Patterson Companies website, www.PattersonCompanies.com. The webcast will be

OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device

Thu, 9 Feb 2012 14:27:00 UT

YARDLEY, Pa.--(BUSINESS WIRE)--The first patients have been successfully enrolled in a phase III study involving the intranasal delivery of sumatriptan powder using the OptiNose bi-directional technology. The trial, named TARGET (AssessmenT of Delivery of Drug via A Novel Device to the IntRanasal Cavity for MiGraine PatiEnTs) will evaluate the safety and efficacy of this novel product – specifically assessing the ability to offer rapid pain relief, sustained freedom from pain and other measures.

Sorin : RISULTATI PRELIMINARI 2011: UTILE NETTO IN AUMENTO DEL 48,5%

Thu, 9 Feb 2012 14:27:00 UT

MILANO--(BUSINESS WIRE)--Sorin (MIL:SRN): Risultati consolidati del Quarto Trimestre 2011: Ricavi pari a €197,9 milioni, in crescita dello 0,8%1 (+1,2% as reported) rispetto al quarto trimestre 2010; Profitto Lordo a €120,3 milioni, pari al 60,8% dei ricavi (59,2% nel quarto trimestre 2010); EBITDA a €38,2 milioni, pari al 19,3% dei ricavi (19,2% nel quarto trimestre 2010); Risultato netto in crescita del 23,8% a €16,0 milioni, pari all’8,1% dei ricavi (6,6% nel quarto trimestre 2010). Risultati

Sorin: Preliminary Results for 2011: Net Profit Increases by 48.5%

Thu, 9 Feb 2012 14:27:00 UT

MILAN--(BUSINESS WIRE)--Sorin (MIL:SRN): Consolidated results for the fourth quarter of 2011: Revenues of €197.9 million, a 0.8%1 increase (+1.2% as reported) over the fourth quarter of 2010; Gross profit of €120.3 million, 60.8% of revenues (59.2% in the fourth quarter of 2010); EBITDA of €38.2 million, 19.3% of revenues (19.2% in the fourth quarter of 2010); Net profit up 23.8% to €16.0 million, 8.1% of revenues (6.6% in the fourth quarter of 2010). Preliminary consolidated results for 2011: R

Array BioPharma Announces Proposed Public Offering of Common Stock

Thu, 9 Feb 2012 14:00:00 UT

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) announced today the pricing of an underwritten public offering of 20,000,000 primary shares of its common stock at a public offering price of $2.60 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $52 million. The offering is expected to close on or about February 14, 2012, subject to customary closing condition

Research and Markets: Thought Leader Insight & Analysis Report - Osteoporosis Q4 2011

Thu, 9 Feb 2012 14:00:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/5a601f/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Osteoporosis Q4 2011" report to their offering. Osteoporosis Thought Leader Panel #53 summarizes an Advisory Board that BOLT International / MedPredict conducted with our Thought Leaders after the ASBMR 2011. The Panel reviewed the highlights (lowlights) from the meeting, and touched on important pipe

Cigna Celebrates a Child’s One-Of-A-Kind Smile During National Children’s Dental Health Month

Thu, 9 Feb 2012 14:00:00 UT

PHILADELPHIA--(BUSINESS WIRE)--Cigna is encouraging parents to get at the root of childhood tooth decay and be a positive role model for good oral health during National Children’s Dental Health Month in February.

Arkansas Office of Health Information Technology Selects OptumInsight for Statewide Health Information Exchange Services

Thu, 9 Feb 2012 14:00:00 UT

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Arkansas Office of Health Information Technology Selects OptumInsight for Statewide Health Information Exchange Services

Orthofix International Launches Centronail Ankle Compression Nailing and Lapidus Plating Systems in the U.S.

Thu, 9 Feb 2012 14:00:00 UT

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today the full U.S. launch of two differentiated internal fixation repair solutions for the foot and ankle market with the Centronail Ankle Compression Nailing and Contours Lapidus Plating Systems. Centronail Ankle Compression Nailing (ACN) System With the U.S. launch of the Centronail Ankle Compression Nailing (ACN) System, Orthofix now has a differentiated solution for hindfoot fusions. This

ExitCare and Xpress Technologies Announce Partnership

Thu, 9 Feb 2012 14:00:00 UT

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Xpress Technologies has expanded its Electronic Health Record (EHR) to include integration of patient education content powered by ExitCare, LLC.

Advaxis to Present at the 14th Annual BIO CEO & Investor Conference

Thu, 9 Feb 2012 14:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis to Present at BIO CEO & Investor

Zynex Expands Internationally – Forms European Subsidiary

Thu, 9 Feb 2012 14:00:00 UT

LONE TREE, Colo.--(BUSINESS WIRE)--Zynex, Inc. (OTCBB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the creation of a European, wholly owned subsidiary in Denmark, which will initially focus on sales and marketing within the European marketplace. Thomas Sandgaard, CEO of Zynex stated, “We believe that considerable revenue opportunities exist in the global medical device marke

MediKeeper Selects High-Tech BtoB PR and Marketing Firm Arketi Group for Marketing Engagement

Thu, 9 Feb 2012 14:00:00 UT

DURHAM, N.C.--(BUSINESS WIRE)--Arketi Group, a high-tech business-to-business public relations and digital marketing firm, has been chosen by MediKeeper to lead strategic marketing.

Celldex Therapeutics to Participate on Therapeutic Workshop Panel at the BIO CEO & Investor Conference

Thu, 9 Feb 2012 14:00:00 UT

NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Thomas Davis, M.D., Senior Vice President and Chief Medical Officer of Celldex Therapeutics, Inc., will participate with other industry executives in a therapeutic workshop panel discussion titled Drugs Need Friends Too – Companion Diagnostics and Drug Development. The panel will be moderated by Steve Brozak, President, WBB Securities LLC, at the 14th Annual BIO CEO & Investor Conference on Tuesda

Research and Markets: Thought Leader Insight & Analysis Report - Psoriasis Q2 2011

Thu, 9 Feb 2012 14:00:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/cd9dd5/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Psoriasis Q2 2011" report to their offering. Psoriasis Thought Leader Panel includes the insights from six internationally recognized psoriasis experts (3 US, 1 Swiss, 1 German, 1 French). This Panel Discusses the Following: 1) What are the key unmet needs that warrant payers reimbursing more than $20

Life Time Fitness Announces Date for Release of Fourth Quarter and Full Year 2011 Financial Results

Thu, 9 Feb 2012 14:00:00 UT

CHANHASSEN, Minn.--(BUSINESS WIRE)--Life Time Fitness, Inc. (NYSE: LTM), The Healthy Way of Life Company, today announced that its fourth quarter and year end 2011 financial results announcement will occur on Thursday, February 16, 2012. A conference call to discuss the results will be held at 10:00 a.m. ET. Bahram Akradi, chairman, president and chief executive officer, Michael Robinson, executive vice president and chief financial officer, and John Heller, senior director, investor relations a

Research and Markets: Health and Fitness Market Report - Focus on Clubs and Equipment - Market Estimated to Reach 4.4bn by 2016

Thu, 9 Feb 2012 13:38:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/22a05e/health_and_fitness) has announced the addition of the "Health and Fitness Market Report - Focus on Clubs and Equipment - UK 2012-2016 Analysis" report to their offering. The health and fitness industry has demonstrated a variable performance over the past 5 years or so. It is estimated that the UK market for health clubs including both the private and public sector was worth 3.8bn in 2011, while the f

Invacare Declares Quarterly Dividend

Thu, 9 Feb 2012 13:36:00 UT

ELYRIA, Ohio--(BUSINESS WIRE)--The Board of Directors of Invacare Corporation (NYSE:IVC) announced that it declared a cash dividend of $.0125 per share on its common shares and $.011364 per share on its Class B common shares payable April 13, 2012 to shareholders of record on April 5, 2012. Invacare Corporation (NYSE:IVC - news), headquartered in Elyria, Ohio, is the global leader in the manufacture and distribution of innovative home and long-term care medical products that promote recovery and

Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference

Thu, 9 Feb 2012 13:31:00 UT

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 3:30 p.m. EST, Thursday, February 16, at the Leerink Swann 2012 Global Healthcare Conference. The conference will be held at The Waldorf Astoria in New York. A live webcast will be available on the Company’s website at www.pumabiotechnology.com. The presentation wi

LTS Nutraceuticals’ BioCalth® Sold on Walmart.com and VitaminShoppe.com

Thu, 9 Feb 2012 13:30:00 UT

FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--LTS Nutraceuticals, Inc. (the “Company”) (OTCBB: LTSN), a developer and manufacturer of nutritional and personal care products, today announced that the Company has begun selling its BioCalth® product on Walmart.com and on VitaminShoppe.com as BioCalth’s initial entry into the U.S. market. The Company recently acquired the brand, expanding its retail product line which includes recognized brands Celadrin® and fit calorie crystals™. These products are sold t

ArQule, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference

Thu, 9 Feb 2012 13:30:00 UT

WOBURN, Mass.--(BUSINESS WIRE)--ArQule announces presentation at Leerink Swann 2012 Global Healthcare Conference.

New Study Shows Lower Rates of Preterm Delivery for Women Receiving Nurse-Administered 17P at Home vs. Office Setting

Thu, 9 Feb 2012 13:22:00 UT

ATLANTA--(BUSINESS WIRE)--Researchers found that women receiving prophylactic 17P through an administration nursing and care management program were more likely to adhere to recommended treatment criteria than in MD office.

Courtagen to Partner with Tetracore in Biodefense Initiative

Thu, 9 Feb 2012 13:20:00 UT

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc. today announced that it has entered into a strategic collaboration with Tetracore, Inc. to develop a next generation biothreat assay.

Bretford Launches EDU 2.0TM Education Furniture System for Connected Learning Environments

Thu, 9 Feb 2012 13:16:00 UT

CHICAGO--(BUSINESS WIRE)--Bretford Launches EDU 2.0TM Education Furniture System for Connected Learning Environments

Oragenics, Inc. Announces Advisory Relationship with Dr. Richard Nagelberg, DDS

Thu, 9 Feb 2012 13:15:00 UT

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Announces Advisory Relationship with Dr. Richard Nagelberg, DDS

Pro Football Hall of Famer Mike Haynes Teams Up with MultiTable.com as National Spokesperson

Thu, 9 Feb 2012 13:11:00 UT

PHOENIX--(BUSINESS WIRE)--Pro Football Hall of Famer Michael Haynes is announced as spokesperson for MultiTable.com - a manufacturer and retailer of height adjustable tables and desks for the home and office.

Acetylon Announces $15 Million Strategic Equity Investment by Celgene Corporation

Thu, 9 Feb 2012 13:01:00 UT

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals announced that Celgene Corporation (NASDAQ: CELG) will invest a total of $15 million in Acetylon via the purchase of Series B-2 Preferred Stock.

Synergy Pharmaceuticals sarà presente alla 14a edizione della conferenza annuale BIO CEO & Investor Conference

Thu, 9 Feb 2012 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP), azienda dedita allo sviluppo di nuovi farmaci per il trattamento di disturbi e patologie gastrointestinali, ha annunciato in data odierna che il suo Presidente e CEO, Gary S. Jacob, Ph.D, parlerà alla 14a edizione della conferenza annuale BIO CEO & Investor Conference. La presentazione del Dr. Jacob si terrà lunedì 13 febbraio 2012 alle 15:30 EST nell'East Foyer del Waldorf Astoria a New York, NY. Informazioni su Synerg

Vortrag von Synergy Pharmaceuticals auf der 14. jährlichen BIO CEO & Investor Conference

Thu, 9 Feb 2012 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP), ein Entwickler neuer Arzneimittel zur Behandlung von Magen- und Darmkrankheiten, gab heute bekannt, dass sein President und CEO Gary S. Jacob, Ph. D., als Referent auf der 14. jährlichen BIO CEO & Investor Conference auftreten wird. Dr. Jacob wird seinen Vortrag am Montag, den 13. Februar 2012 um 15.30 Uhr EST im East Foyer des Waldorf Astoria in New York halten. Über Synergy Pharmaceuticals, Inc. Synergy ist ein biopha

BioMolded Products, LLC Opens Medical Consumables Manufacturing Facility

Thu, 9 Feb 2012 13:00:00 UT

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--New Southern California company specializes in medical-grade, blow molded plastic parts for the biopharmaceutical and life science industries.

BIOTONE Introduces True Balance Massage Gel

Thu, 9 Feb 2012 13:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--BIOTONE True Balance Massage Gel that uniquely combines Mango Butter with fruit oils and botanical extracts to provide a lubricant that is rich, luxurious and long lasting.

Alnylam Scientists Discover Novel Method for Monitoring RNAi Activity in Blood Samples

Thu, 9 Feb 2012 13:00:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics. The new pre-clinical research discovery results were presented at the Keystone Gene Silencing by Small RNAs meeting, being held February

Universal Hospital Services, Inc. Names William C. Mixon as President

Thu, 9 Feb 2012 13:00:00 UT

EDINA, Minn.--(BUSINESS WIRE)--Universal Hospital Services, Inc. (“UHS”), a leading provider of medical equipment management and service solutions, announced today that William C. Mixon has been named President of UHS and will take on the responsibilities for all UHS Sales and Marketing functions. Mr. Mixon will report directly to UHS Chairman and CEO Gary Blackford. “We are very pleased that Bill has joined our team and we are confident he will provide the leadership that UHS needs for continue

SNBL USA Moves Forward with Provantis Preclinical Solution Implementation

Thu, 9 Feb 2012 13:00:00 UT

EVERETT, Wash.--(BUSINESS WIRE)--SNBL USA today announced it is on track with the implementation and launch of Instem’s Provantis® preclinical software solution suite in November 2012.

Isabelle C. Kopec, M.D., F.A.C.P., F.C.C.P., Named Chair of Society of Critical Care Medicine’s Tele-ICU Committee

Thu, 9 Feb 2012 13:00:00 UT

HOUSTON--(BUSINESS WIRE)--Isabelle C. Kopec, M.D., F.A.C.P., F.C.C.P., Named Chair of Society of Critical Care Medicine’s Tele-ICU Committee

bluebird bio to Present at the Leerink Swann 2012 Global Healthcare Conference

Thu, 9 Feb 2012 13:00:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that Nick Leschly, chief executive officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012 at 2:15PM EST at the Waldorf Astoria Hotel in New York City. Mr. Leschly is expected to discuss the company’s vision for developing gene therapies for genetic diseases with high unmet medical n

Axway to Present at HIMSS12 Interoperability Showcase

Thu, 9 Feb 2012 13:00:00 UT

PHOENIX--(BUSINESS WIRE)--Axway, the Business Interaction Networks company, announced today that it will be exhibiting at HIMSS12 in Las Vegas on February 20, 2012. Axway will be presenting in the HIMSS12 Interoperability Showcase – Break the Barriers to Interoperable Healthcare. The Company will showcase its solutions in a live, connected system demonstration use case that represents the Healthcare Secure Exchange Network of the Future. Axway successfully passed all required interoperability te

Agios Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference

Thu, 9 Feb 2012 13:00:00 UT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced that Duncan Higgons, chief operating officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 11AM EST at the Waldorf Astoria Hotel in New York City. Mr. Higgons is expected to discuss the company’s portfolio of cancer metabolism therapeu

Research and Markets: Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011

Thu, 9 Feb 2012 13:00:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/75ef8d/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011" report to their offering. Multiple Sclerosis Thought Leader Panel #14 highlights a series of interviews conducted with experts in September, 2011. For this Panel Medpredict asked their Thought Leaders to engage in a thought exercise with them. The purpose was to designate t

UnitedHealthcare Unseats WellPoint as the Leading Health Insurer according to Mark Farrah Associates

Thu, 9 Feb 2012 13:00:00 UT

KENNEBUNK, Maine--(BUSINESS WIRE)--Mark Farrah Associates (MFA) reports UnitedHealthcare surpassed WellPoint as the top health insurance company in the nation. As of September 2011, WellPoint enrolled 34.355 million people in medical plans whereas UnitedHealthcare enrolled 34.395 million -- a difference of about 40,000 members. MFA analyzed market share and performance of these companies as well as other leading health plans in the U.S. in a recent Healthcare Business Strategy release. MFA found

Synergy Pharmaceuticals effectuera une présentation à l'occasion de la 14e conférence annuelle BIO CEO & Investor

Thu, 9 Feb 2012 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (Nasdaq : SGYP), développeur de nouveaux médicaments destinés à traiter les troubles et les maladies d'ordre gastro-intestinal, annonce ce jour que son président et directeur général, Gary S. Jacob, Ph.D, effectuera une présentation à l'occasion de la 14e conférence annuelle BIO CEO & Investor. La présentation du docteur Jacob aura lieu le lundi 13 février 2012 à 15h30 (HNE) au Foyer est du Waldorf Astoria à New York, dans l'État de Ne

Synergy Pharmaceuticals to Present at 14th Annual BIO CEO & Investor Conference

Thu, 9 Feb 2012 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President and CEO, Gary S. Jacob, Ph.D, will present at the 14th Annual BIO CEO & Investor Conference. Dr. Jacob’s presentation will be given on Monday, February 13, 2012 at 3:30 p.m. EST in the East Foyer of the Waldorf Astoria in New York, NY. About Synergy Pharmaceuticals, Inc. Synergy is a biopharmaceutical company fo

Synergy Pharmaceuticals verzorgt presentatie tijdens 14e jaarlijkse BIO CEO & Investor Conference

Thu, 9 Feb 2012 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP), ontwikkelaar van nieuwe geneesmiddelen voor de behandeling van gastro-intestinale aandoeningen en ziekten, heeft vandaag bekendgemaakt dat de voorzitter en CEO van het bedrijf, Gary S. Jacob, Ph.D, een presentatie zal verzorgen tijdens de 14e jaarlijkse BIO CEO & Investor Conference. De presentatie van dr. Jacob zal plaatsvinden op maandag 13 februari 2012 om 15.30u EST in de East Foyer van het Waldorf Astoria in New Yo

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review for Phase III Program

Thu, 9 Feb 2012 12:55:00 UT

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the

Altheos Announces Initiation of Phase 2a Clinical Trial for its Lead Glaucoma Drug Candidate, ATS907

Thu, 9 Feb 2012 12:30:00 UT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Altheos, Inc., announced today the dosing of the first patient in a Phase 2a clinical trial of its lead investigational candidate, ATS907, a Rho kinase (ROCK)-selective inhibitor in development as a next-generation eye drop for the reduction of elevated intraocular pressure (IOP) in primary open angle glaucoma and ocular hypertension. ATS907 is one of a series of ROCK inhibitor compounds licensed from Asahi Kasei Pharma. Altheos also announced the co

PaxVax Expands Executive Management Team

Thu, 9 Feb 2012 12:30:00 UT

MENLO PARK, Calif.--(BUSINESS WIRE)--PaxVax, developer of innovative and socially responsible oral vaccines against infectious diseases, announced the expansion of its executive management team.

ImmunoCellular to Present at the 14th Annual BIO CEO & Investor Conference

Thu, 9 Feb 2012 12:28:00 UT

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that its president and CEO, Manish Singh Ph.D., will be presenting at the upcoming 14th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh’s presentation will take place on Monday, February 13th, 2012 at 1:00 pm. The presentation will be

Research and Markets: The Middle Eastern Medical Device Market: Facts and Figures 2011

Thu, 9 Feb 2012 12:18:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/582e74/the_middle_eastern) has announced the addition of the "The Middle Eastern Medical Device Market: Facts and Figures 2011" report to their offering. At a time of political upheaval in many countries, this report presents hard-to-find facts, figures and statistics on the economic, demographic and health structure of 18 Middle Eastern countries. Why Middle East, and why now? Tunisia, Egypt, Libya, Jordan

UnitedHealthcare Completes XLHealth Acquisition

Thu, 9 Feb 2012 12:15:00 UT

MINNETONKA, Minn.--(BUSINESS WIRE)--UnitedHealthcare, a UnitedHealth Group (NYSE:UNH) company, has completed its acquisition of XLHealth Corporation, (XLHealth) a sponsor of Medicare Advantage health plans with a primary focus on Medicare recipients with special needs, such as those with chronic illness and those eligible for Medicaid (“dual eligibles”). By building on XLHealth’s model of care, UnitedHealthcare can better serve chronically ill and dual eligible Medicare beneficiaries nationwide.

Sucampo Announces Webcast of Its Presentation at the 14th Annual BIO CEO + Investor Conference

Thu, 9 Feb 2012 12:01:00 UT

BETHESDA, Md.--(BUSINESS WIRE)--Sucampo will webcast its corporate presentation at the 14th Annual BIO CEO + Investor Conference, on Monday, Feb. 13, at 8:30 am Eastern.

NanoViricides Completes a $5 Million Raise in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand

Thu, 9 Feb 2012 12:00:00 UT

WEST HAVEN, Conn.--(BUSINESS WIRE)--Nanoviricides received the final $2.5M tranche of the $5M financing from Seaside yesterday. The Company received the initial tranche of $2.5M in November, 2011.

Cubist Receives CUBICIN Paragraph IV Notice Letter

Thu, 9 Feb 2012 12:00:00 UT

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has received a Paragraph IV Notice Letter from Hospira, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of CUBICIN® (daptomycin for injection). CUBICIN is currently protected by five FDA Orange Book-listed patents, which expire between 2016 and 2028. Hospira’s Notice Letter is directed to all of the patents listed in the Orange Book. Cubist intend

Impax Laboratories Provides Update on Status of Warning Letter Resolution for its Hayward Facility

Thu, 9 Feb 2012 12:00:00 UT

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today provided an update on the status of its resolution of the previously disclosed warning letter issued by the U.S. Food and Drug Administration (FDA) covering its Hayward manufacturing facility. Late last year, Impax received an acknowledgement letter from the FDA stating that it had received a complete response from Impax to the warning letter. However, a satisfactory re-inspection is required to close out the warning

UnitedHealth Group Board Authorizes Payment of Quarterly Dividend to Shareholders

Thu, 9 Feb 2012 12:00:00 UT

MINNEAPOLIS--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) announced today that its Board of Directors, at its meeting on February 8, 2012, authorized payment of a quarterly dividend to shareholders in the first quarter of 2012. The dividend, $0.1625 per share, will be paid on March 19, 2012, to all shareholders of record of UnitedHealth Group common stock as of the close of business on March 5, 2012. About UnitedHealth Group UnitedHealth Group (NYSE: UNH) is a diversified health and well-bein

Covidien to Present at Leerink Swann Conference

Thu, 9 Feb 2012 12:00:00 UT

MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Leerink Swann 2012 Global Healthcare Conference in New York, New York, on February 16, 2012. Charles J. Dockendorff, Executive Vice President and Chief Financial Officer, will discuss the Company in a presentation scheduled to begin at 8:30AM ET. A live audio webcast of the presentation can be accessed at Covidien’s Investor Relations website: http://investor.covidien.co

Galectin Therapeutics to Present Corporate Update at BIO CEO & Investor Conference

Thu, 9 Feb 2012 12:00:00 UT

NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics, Inc. (OTC: GALT), the leading developer of therapeutics that target galectin receptors to treat cancer and fibrosis, today announced that Dr. Peter G. Traber, Chief Executive Officer, President and Chief Medical Officer, is scheduled to present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 14, 2012, at 10:30am ET at the Waldorf- Astoria Hotel in New York City. The presentation will be webcast live at: http:

Research and Markets: Thought Leader Insight & Analysis Report - Psoriasis Q4 2011

Thu, 9 Feb 2012 12:00:00 UT

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/cb9c4e/thought_leader_ins) has announced the addition of the "Thought Leader Insight & Analysis Report - Psoriasis Q4 2011" report to their offering. Psoriasis Thought Leader Panel #21 is a thought exercise conducted with six experts in the management of psoriasis/psoriatic arthritis in November 2011. The purpose of this exercise was to identify their must have branded and generic drugs for their real-wo

Teleflex Announces Fourth Quarter and Full Year 2011 Results and 2012 Outlook Conference Call Information

Thu, 9 Feb 2012 12:00:00 UT

LIMERICK, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that financial results for the fourth quarter and full year 2011, as well as its financial outlook for 2012, will be released before market open on Thursday, February 23, 2012. An investor conference call will be held at 8:00 a.m. (ET) on Thursday, February 23, 2012. The call can be accessed through a live audio webcast on the company’s website, www.teleflex.com. A replay of the call will also be available on the w

Alexion Reports Fourth Quarter and Full Year 2011 Results

Thu, 9 Feb 2012 11:30:00 UT

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN): Fourth Quarter 2011 Financial Highlights: Q4 2011 net product sales increased 46 percent to $227.6 million, compared to $156.0 million in Q4 2010. Q4 2011 GAAP net income increased 82 percent, to $48.2 million, or $0.25 per share, compared to Q4 2010 GAAP net income of $26.5 million, or $0.14 per share. Q4 2011 non-GAAP net income increased 65 percent to $80.5 million, or $0.41 per share, compared to Q4 2010 non-GAAP

Latino Community Leaders, Senior Advocates and Public Health Workers Protest Shutdown of Mission District Geriatric/Youth Mental Health Clinic

Thu, 9 Feb 2012 11:05:00 UT

--(BUSINESS WIRE)--SEIU: When: Noon, Thursday, February 9 Where: Southeast/Mission Geriatric Services Clinic S.F. Department of Public Health 3905 Mission Street, San Francisco Who: Clinic patients and workers, Mission district leaders, union representatives. Leah Berlanga, SEIU 1021 Field Director, 415-602-7317 Eva Royale, community leader, 415-621-2665, 415-623-6096 Gladys Soto, community leader, 415-713-9424 Why: The Department of Public Health is planning the shutdown of the

BioNJ Media Advisory: U.S. Labor Department Assistant Secretary to Visit as Chromocell Marks 100th Employee

Thu, 9 Feb 2012 11:02:00 UT

--(BUSINESS WIRE)--Date: Thursday, February 9, 2012 Time: 1:00 to 2:00 p.m. Location: Chromocell Corporation 685 U.S. Highway One North Brunswick, NJ 08902 CLICK HERE for directions What: U.S. Assistant Secretary of Labor for Employment and Training Joan Oates, will tour the emerging biotechnology company Chromocell Corporation in North Brunswick, NJ to discuss employee training programs as it celebrate the hiring of its 100th employee. Although the company’s personnel are highly educate

BioClinica Reports Record Service Revenue for the Fourth Quarter and Year End 2011

Thu, 9 Feb 2012 11:01:00 UT

NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica reports record service revenue for the fourth quarter and year end 2011, along with its full financial results for the year ended December 31, 2011.

Acorda Therapeutics to Present at Leerink Swann 2012 Global Healthcare Conference

Thu, 9 Feb 2012 11:01:00 UT

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 4:00 pm ET at the Walfdorf=Astoria Hotel in New York, NY. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com, or you may use the link: http://wsw.com/webcast/leerink23/ac

GI Dynamics, Inc. Designates National Obesity Surgery Centre as Center of Excellence in the United Kingdom

Thu, 9 Feb 2012 11:00:00 UT

LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics Designates National Obesity Surgery Centre as Center of Excellence in the United Kingdom

Prestige Brands Holdings, Inc. Reports Fiscal 2012 Third Quarter Sales Increase of 17.3%; Operating Income Up 81.4%; Acquisition of 15 OTC Brands from GSK Completed

Thu, 9 Feb 2012 11:00:00 UT

IRVINGTON, N.Y.--(BUSINESS WIRE)--Prestige Brands Holdings, Inc. (NYSE: PBH) today announced results for the fiscal 2012 third quarter ended December 31, 2011, including net revenues of $106.3 million, an increase of 17.3% over the prior year's comparable quarter of $90.6 million. Net revenues for the nine month period of fiscal 2012 were $307.1 million, an increase of 27.9% over the prior year's comparable period of $240.1 million. This growth is largely driven by the fiscal 2011 acquisitions o

Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012

Thu, 9 Feb 2012 11:00:00 UT

KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the third quarter and first nine months of fiscal year 2012, ended December 31, 2011. Third Quarter 2012 For the third quarter of fiscal 2012 compared to the third quarter of fiscal 2011, revenues were $6,706,000 compared to $3,919,000. Gross profit was $2,827,000, with gross profit margin of

Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2011 Financial Results on February 16, 2012

Thu, 9 Feb 2012 11:00:00 UT

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will host a conference call and live webcast to report its fourth quarter and full year 2011 financial results on Thursday, February 16 at 8:30 a.m. ET. To participate in the conference call, please dial 866-831-6267 (domestic) or 617-213-8857 (international) and reference the access code 14094231. The presentation will be available via a live webcast at: http://ir.acorda.com/phoenix.zhtml?c=194451

CLC bio and VIB Agree on an Academic Regional Site License

Thu, 9 Feb 2012 10:59:00 UT

GHENT, Belgium & AARHUS, Denmark--(BUSINESS WIRE)--Today, CLC bio and VIB, a life sciences research institute in Flanders, Belgium, announced the signing of an academic regional site license agreement for CLC bio's sequence analysis software CLC DNA Workbench. The software will be used across academic institutions in the Flanders region in Belgium, including Universiteit Gent, Katholieke Universiteit Leuven, University of Antwerp, and the Vrije Universiteit Brussel. Herwig Van Marck, Manager of